31 crore people to get corona vaccine in first phase in India, blueprint ready

Posted on 27th Nov 2020 by rohit kumar

Before the arrival of the Corona vaccine, the Priority Group has been finalized in India. In the first phase, 31 crore people will be vaccinated. These include healthcare workers, police, priority group members above 50 years of age, and youth from high-risk groups. The government has also decided that the initial data from two full-shot results from two-dose trials of the Oxford-AstraZeneca vaccine will be considered.

 

Blueprint for vaccine preparation

 

Principal Scientific Advisor K. According to Vijayaraghavan, the National Vaccine Committee headed by Dr. VK Paul has prepared a blueprint for who will be the first to be vaccinated. He told a meeting of the Ministry of Science and The Confederation of Indian Industry (CII) that 31 crore people have been identified, who will be vaccinated between March and May.

 

Vijayaraghavan said, 'One crore health workers in our country, 2 crore of state and central government police, armed forces, home guards, civil defense, 26 crore members of priority group over 50 years of age and below 50 years 1 crore members of the high-risk group will be the first to be vaccinated. Earlier, Union Health Minister Harsh Vardhan has said that the vaccine will start from the first quarter of 2021. 25 crore people are ready to be vaccinated. 40-50 crore doses will be available by July.

 

What data will Oxford consider India?

 

Phase 3 or final phase trials of the Corona Vaccine Coveshield of Oxford University-AstraZeneca have yielded results. On giving two full doses, the FICCI was 62% and when given one half and one full dose, the FICC was 90 percent. On which of these two formulas the data will be considered in India, the head of the National Vaccine Committee, Dr. VK Paul has said that the regulators are examining the data. Whatever decision will be taken will be on a scientific basis. It is not right to make public debate on this data is confidential. At the same time, some other Indian officials say that the American Food and Drug Administration (USFDA) has required at least 50% efficacy to approve the vaccine. In this case, the results of two full dosage formulas are also good.

 

European Union will take its first vaccine this year

 

European Union leaders expect the first vaccine to be introduced in December. By the way, the European Medicines Agency, without naming any company, said that in the next few days, some companies can apply for approval. Pfizer and Biotech are at the forefront of the regulatory approval process. Apart from Pfizer, American company Moderna and British company AstraZeneca and Oxford University have also announced the results of Phase-3 trials of their vaccine. Pfizer has also applied for approval in the US. The process of applying the vaccine to high-risk patients has already started even before the results of Phase-3 trials in China and Russia. For this, China has given emergency approval to four vaccines and Russia two.

 

UK regulator will investigate the results of the Oxford vaccine

 

The British government has formally asked the country's drug regulator to examine the Phase-3 results of AstraZeneca and Oxford University's vaccine-Kovyshield. The British government has taken this step amid questions arising over the initial results of the trials. Earlier, the UK government had also instructed the medical regulator to check the efficacy of Pfizer's vaccine. The drug regulator says that any vaccine will be approved even after meeting the criteria on the issue of safety, quality, and affixation.

 

AstraZeneca will conduct a new global clinical trial

 

AstraZeneca said it would conduct a global clinical trial to see its vaccine affixation. However, regulatory approval in the UK or EU will not be delayed. There may be a delay in seeking approval from the USFDA for vaccines in the US. During the trials, 2,741 volunteers received half + one dose, while 8,895 people received two full doses. In such a situation, the company faced difficulties in proving effectiveness in the group.

 

Russian vaccine will remain effective with Oxford vaccine

 

Russia's Gamalaya Research Institute has claimed that its Sputnik V vaccine may increase Astyzyneca-Oxford's CoviShield's Efficacy. Gamalaya Institute said on social media - "Oxford's two full dose affixes have been 62%. If new clinical trials begin, we suggest Sputnik V Human Adenoviral Vector Shot with Kovyshield, this will increase the Efficiency Two. Adding the vaccine can lead to significant re-vaccination results. "

 

Pfizer vaccine will be approved in Canada in December

 

Canadian drug regulator, Health Canada, has said it will approve Pfizer-BioNotech's COVID-19 vaccine around December. Supriya Sharma, Senior Medical Advisor at Health Canada, said that the vaccine has been at the forefront of Health Canada's review. A final decision on Pfizer's vaccine may also be taken in Canada's neighboring country of America in December and it can be approved for emergency use.